Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma

Published:2024-05-22 Issue:10 Volume:16 Page:9047-9071
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Pan Yitong¹²,Zhu Qiyao¹,Hong Ting¹,Cheng Jun³,Tang Xinhui¹

Affiliation:

1. The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha 410013, Hunan, China

2. CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China

3. Department of Spine Surgery, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China

Publisher

Impact Journals, LLC

Reference40 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.;Bray;CA Cancer J Clin,2021

2. Targeting ferroptosis as a vulnerability in cancer.;Gan;Nat Rev Cancer,2022

3. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.;Xie;Int J Surg,2022

4. Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency.;Voon;Mol Cancer,2023

5. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.;Delord;JAMA Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP